- Condition: Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
Interventions: Drug: TA-650; Drug: Polyethylene Glycol-treated Human Immunoglobulin (VGIH)
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified May 2012 - Condition: Pediatric Ulcerative Colitis
Intervention: Drug: TA-650
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified April 2012 - Condition: Pediatric Crohn's Disease
Intervention: Drug: TA-650
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified April 2012 - Conditions: Behcet's Disease; Behcet Syndrome; Neuro-Behcet's Disease
Intervention: Drug: TA-650
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified February 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: TA-7284 Low; Drug: TA-7284 High
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified January 2012 - Condition: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Drug: MCI-186; Drug: Placebo; Drug: MCI-186 in open label phase
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified December 2011 - Condition: Chronic Hepatitis C
Interventions: Drug: MP-424 (generic name:Telaprevir); Drug: Ribavirin; Drug: Peginterferon alfa-2b
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified November 2011 - Condition: Chronic Hepatitis C
Interventions: Drug: MP-424 (generic name:Telaprevir); Drug: Ribavirin; Drug: Peginterferon alfa-2b
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified November 2011 - Condition: Perennial Allergic Rhinitis
Interventions: Drug: TAU-284; Drug: TAU-284; Drug: Placebo
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Completed - verified March 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: TA-7284 Low; Drug: TA-7284 High; Drug: Placebo
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Active, not recruiting - verified February 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: TA-7284-Low; Drug: TA-7284-High
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Active, not recruiting - verified February 2012


